Hypertensive patients with altered circadian blood pressure (BP) profile experience greater repercussion of hypertension on target organs and a higher risk of cardiovascular events, compared with those with physiological variations in BP. It has been demonstrated in animal models, that circadian variations in BP depend on several regulatory systems, in particular the nitric oxide-cGMP 1 pathway. eNOS298 Glu/Asp polymorphism is a functional variant and may alter the amount of NO generated or eNOS activity. 2 The objective of the present study was to find out whether eNOS298 gene polymorphism affects circadian BP regulation in 110 healthy subjects and 155 nevertreated hypertensive patients recruited at Hypertension Units in Grenoble, Toulouse and Lille (France).
The inclusion criteria were: age between 20 and 65 years; no chronic disease; normal lipid levels (low-density lipoprotein cholesterol o1.90 g/l and triglycerides o2 g/l); and no concomitant treatments.
BP measurements were taken as recommended by JNC VII. Echocardiogram, measurement of pulse wave velocity, and analysis of BP and heart rate (HR) variability by spectral analysis for 20 min with the patient lying down were performed as described previously. 3 The ambulatory BP measurement was carried out with a Spacelabs 90207 s monitor (Spacelabs International, Redmond, WA, USA). Measurements were made every 15 min over a 24-h period. The following parameters were studied: mean systolic BP (SBP) and diastolic BP (DBP), over the full 24 h, during the day (0700 to 2200) and night (2200 to 0700). The fall in nocturnal BP relative to the daytime value was calculated for SBP and DBP as a percentage and an absolute value.
In hypertensives, circadian BP regulation is considered to be preserved if the mean nocturnal SBP falls by more than 10% relative to the mean daytime SBP ('dipper' patient) and altered if the mean nocturnal BP falls by less than 10% ('nondipper' patient). 4 All the subjects were genotyped by polymerase chain reaction amplification using previously described procedures (http:/genecanvas.idf.inserm.fr). 5 All subjects gave their informed written consent.
Normally distributed variables were expressed as mean7s.d. Comparisons were made using Student's t test or analysis of variance. To evaluate the independence of the associations observed, a stepwise multiple regression analysis was performed. Values of Po0.05 were considered to be significant.
The hypertensive patients were older than the control subjects (50.8710.4 years vs 47.978.9 years, P ¼ 0.05), with a higher male/female ratio (96/54 vs 50/61, P ¼ 0.003), Hypertensives have a higher left ventricular mass index (LVMI) (97726 vs 80718 g/m 2 , Po0.001), higher PWV(10.572.4 vs 8.871.6 m/s, Po0.001) and a lower spectral power at high frequencies of variability of heart rate (HRhf) (30716 vs 37718 nu, P ¼ 0.002).
The percentage variation in BP between day time and night time were not statistically different between hypertensives and controls.
The distribution of eNOS G298A genotypes is in accordance with Hardy-Weinberg equilibrium (normotensives patients: Glu/Glu: 42, Glu/Asp: 50, Asp/Asp: 19, hypertensives patients: Glu/Glu: 66, Glu/Asp: 54, Asp/Asp: 30). HR clinical or ambulatory BP, spectral analysis, BMI, LVMI, PWV, cholesterol and glycaemia did not differ according to the G298A genotype in the control and hypertensive groups.
The fall in SBP or DBP in both normotensive and hypertensive patients was greater in those carrying the eNOS298 Asp allele (Normotensive patients/ SBPF (%): À12.674.8 vs À10.175.6, P ¼ 0.01, DBPF (%): À17.776.4 vs À1576, P ¼ 0.03. Hypertensive patients/SBPF (%): À13.675.3 vs À11.576.6, P ¼ 0.03, DBPF (%): À17.476.7 vs À14.877.6, P ¼ 0.03). This relationship is found whether BP fall is expressed in absolute values or as a percentage of diurnal BP. The percentage of dipper hypertensives for SBP was higher in patients carrying the Asp allele (73.2 vs 57.6%, P ¼ 0.046).
In univariate analysis, the variables associated with the fall of nocturnal BP are retained in the multivariate analysis. After adjustment for covariates, the eNOS298 Asp allele remained significantly associated with a greater fall in nocturnal DBP and SBP in healthy subjects and hypertensives ( Table 1) .
The main result of our study is that the amplitude of nyctohemeral variations in BP partly depends on the NO pathway and is particularly associated with eNOS298 Glu/Asp genetic polymorphism, in both normotensive and hypertensive subjects. Hypertensive patients carrying the Asp allele for eNOS298 Glu/Asp polymorphism are most frequently dippers.
Apart from its role in regulating endothelialdependent vasodilation, some animals work suggests that the eNOS may be important in regulating the autonomic nervous system 6 and physiological circadian rhythms.
7 L-NAME (N w -nitro-L-arginine methyl ester) inhibition of NO synthase activity leads to hypertension and even reversal of the circadian BP rhythm in rats. 1 These results are supported by several studies which have shown a disturbance in circadian rhythms in genetically modified mice (eNOS-knockout mice). 7 The results of our study agree with this work and support the role of eNOS in circadian BP regulation in humans.
Central regulation of nyctohemeral BP variations is provided by the autonomic nervous system. There are nyctohemeral variations in activity and sympathetic/parasympathetic equilibrium. The level of circulating plasma catecholamine falls with the nocturnal fall in BP and rises with the high morning BP. 8 A study of autonomic nervous system activity by analysing the variability in HR, shows reduced activity at night in non-dipper hypertensive patients. 4 These variations in circadian rhythms cannot be studied properly with a single daytime measurement of baseline BP or HR variability. This explains why some studies find reduced variability in BP or HR studied by spectral analysis in nondipper subjects, 3 whereas other studies do not find this difference. 4 It is not surprising that in spite of the link to circadian rhythms, we did not find any association between eNOS298 Glu/A polymorphism and spectral analysis parameters.
In addition to a possible central effect, genetic polymorphism of the eNOS gene could also alter circadian variations in BP through an effect on peripheral vascular reactivity. Patients with the Asp298 variant of eNOS polymorphism record an increase in vasoconstrictive response to phenylephrine 9 and an increase in the vasopressive reaction to stress. 10 Patients carrying the Asp 298 variant may also display increased vascular reactivity to physiological circadian variations in circulating catecholamine levels, 8 which would cause an increase in the amplitude of BP variations between day and night.
We did not find any link between hypertension and genetic eNOS Glu298Asp polymorphism, which is in accordance with most published studies. 11 As in other studies, we did note an inverse relationship between the percentage fall in BP at night and the LVMI. However, like in Karvonen's study, 11 we did not find an association between eNOS298 polymorphism and the LVMI. One possible explanation is that the effect of eNOS298 polymorphism on nocturnal fall in BP is moderated, with moderate effect on the LVM, which was not measurable in our population.
The eNOS is present and is involved at many levels of the cardiovascular system. The moderated effect of allele Asp298 on the nocturnal fall in BP, potentially favourable to cardiovascular prognosis 12 is probably counterbalanced by its direct negative effect on the arterial and coronary artery walls. These different effects of eNOS could explain its association in the literature with a discrete increase in the risk of ischaemic cardiopathy and cardiovascular events.
Our results support the role of the NO pathway in the circadian regulation of BP. The Asp298 variant of NOS is particularly associated with a steeper fall in nocturnal BP, independent of the BP level. The fall in nocturnal BP is a powerful risk factor for target organ damage in hypertensive patients and this finding may have important prognostic implications. 
